Zaynich (zidebactam/cefepime- WCK 5222) has been granted a susceptibility breakpoint of 64 mg/L for around 10 gram negative pathogens showing high resistance rates by the Clinical and Laboratory ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC today announced the peer-reviewed publication of data from the completed ReSTORE phase 3 global clinical trial evaluating REZZAYO ® ...
This presentation will give an update about easing the administrative burden on the lab to assess compliance with CLSI/FDA breakpoints. Topics addressed included FDA 510(k) approvals, the VITEK® V9.04 ...
Why mismatched resistance thresholds between CLSI and EUCAST could be masking the true scale of antimicrobial resistance in the environment. How can global standardization fix this problem? Study: ...
WAYNE, Pa.--(BUSINESS WIRE)--The Clinical and Laboratory Standards Institute announces the publication of its annually updated antimicrobial susceptibility testing (AST) supplement M100—Performance ...
This marked the first instance in the US, where Zaynich had been used to combat a complex infection caused by extreme-drug-resistant pseudomonas, the company said. The announcement on Friday, sent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results